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Background: Cumulin is a newly identified heterodimeric member of the TGF- family.
Results: Mature cumulin potently stimulates granulosa cell signaling and function, whereas pro-cumulin promotes oocyte
quality.
Conclusion: Formation of cumulin and its potent actions are likely to be central to oocyte paracrine signaling and mammalian
fecundity.
Significance: The discovery of cumulin provides unique opportunities to improve female fertility in mammals.
Growth differentiation factor 9 (GDF9) and bone morphoge-
netic protein 15 (BMP15) are oocyte-specific growth factors
with central roles in mammalian reproduction, regulating spe-
cies-specific fecundity, ovarian follicular somatic cell differenti-
ation, and oocyte quality. In the human, GDF9 is produced in a
latent form, the mechanism of activation being an open ques-
tion. Here, we produced a range of recombinant GDF9 and
BMP15 variants, examined their in silico and physical interac-
tions and their effects on ovarian granulosa cells (GC) and
oocytes. We found that the potent synergistic actions of GDF9
and BMP15 on GC can be attributed to the formation of a het-
erodimer, which we have termed cumulin. Structural modeling
of cumulin revealed a dimerization interface identical to
homodimeric GDF9 and BMP15, indicating likely formation of
a stable complex. This was confirmed by generation of recombi-
nant heterodimeric complexes of pro/mature domains (pro-cu-
mulin) and covalent mature domains (cumulin). Both pro-cu-
mulin and cumulin exhibited highly potent bioactivity on GC,
activating both SMAD2/3 and SMAD1/5/8 signaling pathways
and promoting proliferation and expression of a set of genes
associated with oocyte-regulated GC differentiation. Cumulin
was more potent than pro-cumulin, pro-GDF9, pro-BMP15, or
the two combined on GC. However, on cumulus-oocyte com-
plexes, pro-cumulin was more effective than all other growth
factors at notably improving oocyte quality as assessed by sub-
sequent day 7 embryo development. Our results support a
model of activation for human GDF9 dependent on cumulin
formation throughheterodimerizationwithBMP15.Oocyte-se-
creted cumulin is likely to be a central regulator of fertility in
mono-ovular mammals.
In this study, we consider the unique interaction of two
members of the TGF- family: growth differentiation factor 9
(GDF9)2 and bone morphogenetic protein 15 (BMP15). These
two closely related proteins are oocyte-secreted factors essen-
tial for fertility in mammals (1). The primary role of GDF9 and
BMP15 is to act on the cells surrounding the oocyte, known as
granulosa cells (GC), which in turn supply the oocyte with the
support necessary for future healthy embryo/fetal development
(2). As with all members of the TGF- family, GDF9 and
BMP15 are produced as pro-proteins, consisting of an N-ter-
minal proregion and a receptor binding C-terminal mature
region. Activation of these factors requires proteolytic pro-
cessing by a furin-like protease (3, 4). For most TGF- mem-
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bers, the processed mature domains signal as covalently linked
homodimers, although covalent heterodimers are also known
(inhibin A and B (5)). GDF9 and BMP15 are unusual within the
TGF- family in that they (together with GDF3 and Lefty1/2)
lack the cysteine residue involved in forming themature region
intersubunit disulfide bond (6). Despite this, mature GDF9 and
BMP15 are thought to maintain the canonical dimer architec-
ture of other TGF- ligands and signal as noncovalent dimers.
As with all members of the TGF- family, GDF9 and BMP15
signal via cell surface receptors, which activate intracellular
Sma- andMad-related (SMAD) proteins by phosphorylation of
critical residues, which subsequently regulate the transcription
of various genes (1). The receptors are Ser/Thr kinases and are,
on the basis of distinct features in the cytoplasmic domain,
referred to as either type I (activated by the relevant type II
receptor) or type II (constitutively active) receptors. Following
prodomain displacement, BMP15 binds to complexes of BMP
receptor type II (BMPRII) and activin receptor-like kinase 6
(ALK6), thereby leading to activation of the SMAD1/5/8 intra-
cellular pathway (7, 8). Mature GDF9 binds BMPRII and ALK5
and signals through the SMAD2/3 pathway (9–11).
GDF9 and BMP15 are also functionally unusual within the
TGF- family, in that they show remarkable species differences
in their activity. Notably, human GDF9 is latent, because it
remains associated with its prodomain, whereas mouse GDF9
is particularly potent, because of its prodomain being readily
displaced (3, 12, 13). By contrast, human BMP15 is recombi-
nantly produced in an active form in mammalian cell culture,
whereas mouse BMP15 is not expressed under the same condi-
tions (4). The species-specific differences in expression and
activity of these oocyte-secreted growth factors is principally
due to alterations in a small number of amino acids in the
prodomains (BMP15) or mature domains (GDF9), which affect
complex formation or stability, respectively (3, 4, 13). Hence,
the relative levels of oocyte expression of BMP15 and GDF9
varymarkedly across species, whereby themono-ovular phe-
notype (i.e. low fecundity) is characterized by balanced
BMP15:GDF9 ratios, whereas polyovular species (high
fecundity) express predominately GDF9 (14). As such,
GDF9, but not BMP15, is essential for fertility in the mouse
(15, 16), whereas both are required in mono-ovular species,
such as sheep (17, 18).
Interactions at the genetic level between these two proteins
have been observed in both mice (16) and sheep (1, 18). Evi-
dence for GDF9/BMP15 physical interactions have also been
provided by co-immunoprecipitation results (19, 20), and a
number of functional studies have demonstrated marked syn-
ergistic interactions between these two proteins (20–23).
Recently, Peng et al. (24) have provided evidence that het-
erodimerization of GDF9 and BMP15 gives rise to a more
potent ligand that signals solely via the SMAD2/3 pathway.
In the current study, we hypothesized that humanGDF9 and
BMP15 form a stable heterodimer that has potent actions on
mural GC, cumulus GC, and oocyte development. We provide
the first evidence of a purified BMP15-GDF9 heterodimer. We
find that both the promature form and a covalent mature form
of the heterodimer are particularly potent and are dual pathway
activators, signaling via the SMAD2/3 and SMAD1/5/8 path-
ways. Interestingly, only the promature heterodimer is capable
of improving oocyte quality, indicative of the crucial function
that the prodomain plays in the functioning of these proteins.
In deference to its potent activation of cumulus cells and to
align with the existing nomenclature for the othermajor repro-
ductive TGF- superfamily heterodimer, inhibin, we have
called this new heterodimer cumulin.
Experimental Procedures
Expression Plasmids, Stable Cell Lines, and Protein
Production—Expression cassettes encoding wild type human
GDF9 or BMP15 or mouse GDF9 (mGDF9) were synthesized
(Genscript USA, Inc., Piscataway, NJ) incorporating the rat
serum albumin signal sequence at the 5 end followed by
sequences encoding for His8 and StrepII affinity tags at the N
terminus of the respective proregion. The various human
GDF9 and BMP15 Ser-Cys mutants (Ser418 inGDF9 and Ser356
in BMP15) used in this study were derived from expression
cassettes (Genscript USA, Inc., Piscataway, NJ) incorporating
the glutamate receptor GluR-D subunit signal sequence
(MRIICRQIVLLFSGFWGLAMG) at the 5 end followed by
sequences encoding for the FLAG tag (a design based onKuusi-
nen et al. (25)) and His6 affinity tag at the N terminus of the
respective proregion (as used previously (8)). All the cDNA
fragments were cloned into the pEF-IRES expression vector
(26).
HEK293T cells were obtained from the American Type Cul-
ture Collection and cultured in DMEM (Invitrogen) containing
10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin (Sigma), and
100 g/ml streptomycin. The different expression plasmids
were transfected intoHEK293T cells using Lipofectamine 2000
(Invitrogen) following the manufacturer’s instructions. Stable
cell lines were established via puromycin selection. For produc-
tion of cells producing pro-cumulin, HEK293T cells were co-
transfected with both an expression plasmid for human GDF9
ofwild type sequence, incorporating no epitope tags, alongwith
the expression plasmid for wild type human BMP15 (His8/Stre-
pII-tagged), as described above. For production of cells produc-
ing cumulin (as a covalently stabilized form), HEK293T cells
were co-transfected with expression plasmids encoding human
GDF9 and BMP15 as the Ser-Cys mutant forms, as described
above.
The mature regions of GDF9 (12), BMP15 (27) and the
BMP15 Ser-Cys mutant (8) were produced and purified as pre-
viously described. Cells producing pro-GDF9, pro-mGDF9,
pro-BMP15, pro-cumulin, or covalent cumulin were grown to
near confluence, and growthmediumwas then replaced by pro-
duction media containing DMEM/F12 GlutaMAX, 0.1 mg/ml
BSA (Sigma), 25 IU/ml Fragmin (Pfizer), 100 units/ml penicil-
lin, and 100 g/ml streptomycin (Sigma). After 48 h of incuba-
tion, the conditioned culture medium was collected.
Chromatography—Production medium containing pro-
GDF9, pro-BMP15, or pro-cumulin was modified to include 10
mM imidazole, 500 l of protease inhibitor mixture (Thermo
Scientific), 500 l of phosphatase inhibitor mixture (Calbi-
ochem, Alexandria, Australia) and subsequently adjusted to pH
7.4. Invitrogen nickel-nitrilotriacetic acid-agarose resin was
incubatedwith conditionedmediumon a rotary agitator at 4 °C
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for 2 h and centrifuged at 900 rpm for 5 min, and the superna-
tant was removed. The His-tagged target protein was eluted
from the nickel-nitrilotriacetic acid-agarose using elution
buffer (PBS/500 mM imidazole) and stored in LoBind tubes
(Eppendorf, Hamburg, Germany) at 80 °C. Cumulin (the
covalently stabilized form) was produced and purified as above,
with the exception that the mature region was eluted from the
IMAC resin via a 7 M urea wash. This material was then loaded
onto a reverse phase HPLC column equilibrated with 0.1%
TFA, and the differentmature region forms (i.e.GDF9, cumulin
and finally BMP15) were eluted via a linear gradient of acetoni-
trile. The fractions were stored in LoBind tubes at80 °C.
Silver Staining, Western Blotting, and Protein Quanti-
fication—Fractions from the cumulin reverse phaseHPLCwere
prepared for electrophoresis by lyophilizing 5 l and resus-
pending in SDS-PAGE loading bufferDTT. All samples were
heated at 95 °C for 5 min and then loaded onto a Mini
PROTEAN TGX 4–15% gel (Bio-Rad). After 40 min at 150 V,
the gels were used for silver staining orWestern blotting. Silver
staining was carried out following the manufacturer’s instruc-
tions using a silver quest staining kit (Invitrogen). ForWestern
blotting, proteins were transferred to a Hybond-ECL mem-
brane (GE Healthcare) for 75 min at 100 V. The membranes
were blocked with 2% blocking reagent (supplied in an ECL
Advance kit; GE Healthcare) diluted in TBS containing 0.1%
(v/v) Tween 20 for 1 h at room temperature. Subsequently the
membranes were incubated with anti-GDF9 antibody (mAb53
(28)) or anti-BMP15 antibody (mAb28 (27)) diluted 1:5000 at
4 °C overnight, followed by incubation with goat anti-mouse
IRDye TM800CWantibody diluted 1:10,000, for 1 h in the dark.
Fluorescence intensity was determined using an Odyssey infra-
red imaging system (Licor Bioscience, Lincoln, NE). The vari-
ous purified forms of GDF9 or BMP15 were quantified via
Western analysis relative to recombinant mGDF9 or hBMP15
standards, respectively (R&D Systems).
Granulosa Cell Bioassays—Bioactivities of pro-forms and/or
mature forms of BMP15, GDF9, and cumulin were compared
using primary mouse mural GC and a human granulosa tumor
cell line (COV434). The mouse granulosa cell [3H]thymidine
incorporation bioassay was performed using standard proce-
dures as previously described (28, 29). In brief, mural GC were
collected from 129/Sv mice 44–46 h after gonadotropin prim-
ing. Cells were cultured at 37 °C in 5% CO2 in protein-free
mediumat 2 105 cells/mlwith treatments for 18 h followedby
a further 6 h with 15.4 kBq [3H]thymidine (PerkinElmer Life
Sciences). Granulosa cell [3H]thymidine incorporation was
assessed using aWallacMicrobeta plate counter as an indicator
of cell DNA synthesis. Each treatment was performed in dupli-
cate, and the experiments were replicated three to six times.
The relative capacity of BMP15, GDF9, and cumulin to acti-
vate SMAD signaling was assessed with luciferase assays using
human COV434 cells (3, 30). In brief, cells were plated at 33
103 cells/well in 96-well plates in complete medium (DMEM
supplemented with 10% FCS) at 37 °C in 5% CO2. After 24 h of
incubation, cells were transfected (130 ng/well) with a BMP-
responsive reporter, BRE-luciferase, or an activin/TGF-
responsive reporter, A3-luciferase, using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions for
24 h. The cells were treated with BMP15, GDF9, or cumulin
variants for 16 h. The mediumwas then aspirated, and the cells
were solubilized in solubilization buffer (25 mM glycylglycine,
pH 7.8, 15mMMgSO4, 4mMEGTA, 1% (v/v) TritonX-100, and
1 mM dithiothreitol), and luciferase reporter activity was mea-
sured as previously described (30).
RT-PCR—Mural GC were collected from 21–26-day-old
C57BL/6 DBA F1 hybrid female mice 46 h after intraperito-
neal administration of gonadotropin priming.Mice weremain-
tained in accordance with the Australian Code for the Care and
Use of Animals for Scientific Purposes and with the approval of
the University of New SouthWales Animal Ethics Committee.
Mural GC (1 105 live cells per 24-plate well) were cultured for
18 h in bicarbonate-buffered MEM (Gibco Life Technologies)
supplemented with 3 mg/ml BSA (Sigma-Aldrich). The cells
were then treated for 6 h with freshmedium containing recom-
binant human FSH (50 mIU/ml; Puregon; Organon, Oss, The
Netherlands) plus the following treatments, as indicated: 100
ng/ml cumulin, 100 ng/ml pro-cumulin, 100 ng/ml pro-mature
GDF9, 100 ng/ml pro-mature BMP15, or 50 ng/ml each of pro-
mature GDF9  pro-mature BMP15 when added together.
RNA extraction, reverse transcription, and quantitative PCR
were performed as previously described (31) using their
reported primers; however, PCRs were performed on a Roche
LightCycler 480, and results are expressed as raw gene expres-
sion levels relative to the geometricmeans of two housekeeping
genes (Mrpl19 and Ppia) using the 2(CT) method. The data
are means S.E. of four replicate experiments.
Oocyte Quality Assay—The effects of treatments on oocyte
quality (oocyte developmental competence) were assessed by
treating cumulus-oocyte complexes with the different growth
factors during the oocyte in vitromaturation (IVM) phase, fol-
lowed by in vitro fertilization and embryo culture and assess-
ment of subsequent blastocyst yield and quality. We chose to
use a well established porcine model of low oocyte develop-
mental competence, because this experimental model better
approximates the complexities of human oocyte developmen-
tal competence than that of murine oocytes. This model uses
oocytes from small antral follicles collected from abattoir-de-
rived ovaries from gilts (peripubertal female pig) (13, 32–34).
The methods used were as per recently described in detail (13,
34). In brief, cumulus-oocyte complexes were aspirated from
small antral follicles (2–4 mm) and matured in protein-free
porcine oocyte maturation basic IVM medium (35), supple-
mented for the first 22 h of IVMwith 1mMdibutyryl-cAMPand
100 ng/ml amphiregulin (R&DSystems) and treatedwith either
vehicle (control), 20 or 100 ng/ml pro-cumulin, 20 or 100 ng/ml
mature cumulin, 100 ng/ml pro-GDF9, 100 ng/ml pro-BMP15,
or 100 ng/ml of each of pro-GDF9  pro-BMP15. Cumulus
expansion was assessed at 22 h of IVM and scored as per stan-
dard criteria (36, 37). At 22 h, cumulus-oocyte complexes were
washed and matured for a further 22 h in porcine oocyte mat-
uration without supplements or treatments (13, 33, 34). There-
after, in vitro fertilization, in vitro embryo production, and
assessment of blastocysts was performed as previously
described (13). Five replicate experiments were performedwith
180 oocytes/replicate.
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Molecular Modeling—To obtain three-dimensional struc-
ture models for mature human GDF9, mature human BMP15,
and cumulin, homology modeling was performed using either
the software SWISS-Modeler or a manual approach. To iden-
tify the most suitable structure template, the sequences of
GDF9 and BMP15 were blasted against the protein sequences
present in the Protein Data Bank, revealing that both oocyte
factors exhibit the highest sequence homology (32–33% iden-
tity) to either BMP2 or GDF5. For manual modeling the
sequences of themature region of GDF9 and BMP15 were then
aligned to the amino acid sequence of the identified templates,
i.e. BMP2 (Protein Data Bank entry 3BMP and 1REW (chains A
and B) and 3BK3 (chains A and B)) and GDF5 (Protein Data
Bank entry 1WAQ) using the software CLUSTALW. A model
of human GDF9 comprising residues Asn327–Arg430 was then
built manually by replacing amino acid residues in the BMP2
template (chains A and B of Protein Data Bank entry 3BK3)
employing the tool ProteinDesign of software package
Quanta2008 (MIS Accelrys, San Diego, CA). A single amino
acid insertion at the end of helix 1 found in GDF9 (when
compared with the template BMP2) was rebuilt manually. For
modeling of human BMP15 (comprising residues Asn289–
Arg392), the same approach was applied but using the structure
of human GDF5 (Protein Data Bank entry 1WAQ) as BMP15,
similar to GDF5, binds specifically the BMP receptor BMPR1b.
Both initial models were subsequently refined first by perform-
ing rotamer searches using the tool X-BUILT of the software
Quanta2008 to identify side chain conformations not leading to
van der Waals clashes. Then energy minimization runs were
performed employing only geometrical but no electrostat-
ic energy terms using Quanta2008 and the forcefield
CHARMm27. First, all backbone atoms were kept fixed, and
only side atoms were allowed to move but restrained by har-
monic positional restraints (5 kcal mol1 Å2) to minimize
atom movements. After energy minimization of side chain
atoms converged, these restraints were removed, and the posi-
tions of the backbone atoms were refined by applying a strong
harmonic potential (25 kcal mol1 Å2). The final models of
GDF9 and BMP15 exhibit good backbone and side chain geom-
etry. The structure models for both homodimeric factors are
highly similar, yielding a root mean square deviation of only
1.1Å for 164 C carbons. Only 40 residues, which are located
either in the fingertips or the loop N-terminal of helix 1,
exhibit differing conformations, which may be due to selecting
different template structures for the models and does not
reflect inherent structural differences between GDF9 and
BMP15.
The model of cumulin was then built by superimposing the
three-dimensional models of homodimeric GDF9 and BMP15
and selecting one chain of each structure to form a heterodi-
meric assembly. Because of the almost identical amino acid
composition in the dimer interface, the model of cumulin
required very minor minimization, which was performed by
rotamer searches for side chains with close contacts. The het-
erodimeric noncovalent form of cumulin was then converted
into the covalent form by exchanging the serine residues Ser356
in BMP15 and Ser394 in GDF9 against cysteines and connecting
both sulfur atoms to form the thioether bond. The disulfide
bond was subsequently refined by a short energy minimization
run to obtain a thioether bond of correct length.
Statistical Analysis—For mRNA expression data, differences
between means were assessed by one-way analysis of variance
followed by Tukey’s multiple comparison test. Similarly, effects
of treatments on embryo yield were assessed by one-way anal-
ysis of variance on arc-sine transformed data followed by a least
significant difference post hoc test. Cumulus expansion data
were assessed by a Kruskal-Wallis one-way analysis of variance
on ranks followed by a Dunnett’s post hoc test. p 	 0.05 was
considered statistically significant.
Results
The various forms of GDF9, BMP15, and cumulin analyzed
in this study were as follows: 1) pro-forms: noncovalent homo-
and heterodimers of the promature regions of BMP15 and
GDF9 (the form in which these proteins are secreted from the
cell); 2) mature forms: noncovalent homo- and heterodimers of
the mature regions of BMP15 and GDF9 (the form in which
these proteins bind to their signaling receptors); and 3) covalent
forms: covalent homo- and heterodimers of themature regions
of BMP15 and GDF9 (stabilized versions of the mature growth
factors).
GDF9/BMP15 Synergism Is Mediated by Heterodimer (i.e.
Cumulin) Formation—We have consistently observed GDF9
and BMP15 interacting in a synergistic manner, whether in
their pro-forms (i.e. as isolated pro/mature complexes; Fig. 1)
or as purifiedmature proteins (23, 38). The extracellular forma-
tion of a BMP15/GDF9 heterodimer, which we have termed
cumulin, could underlie this potent synergism. To directly test
this possibility, we generated a covalent BMP15homodimer (by
replacing Ser356 with the corresponding cysteine found in other
TGF- proteins), which would be incapable of forming cumu-
lin in the presence of wild type GDF9.
FIGURE 1. Pro-forms of BMP15 and GDF9 synergize. Pro-hBMP15 syner-
gizes with pro-mouse GDF9 and also with pro-human GDF9, which is natu-
rally latent. Bioactivity was assessed by [3H]thymidine incorporation in pri-
mary mousemural GC. The various pro-proteins were produced in HEK-293T
cells with N-terminal His tags attached to their prodomains allowing purifica-
tion by IMAC.
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Covalent human BMP15 mature region homodimer
(BMP15S:C) was purified and tested for its ability to synergize
with human GDF9 (mature region homodimer) in a mural
granulosa cell proliferation assay. At the low doses tested,
GDF9, BMP15, and BMP15S:C did not promote proliferation;
however, the GDF9BMP15 combination showed potent syn-
ergism (Fig. 2A). In contrast, this synergism was not observed
with the GDF9BMP15S:C combination. Because we have pre-
viously shown thatGDF9/BMP15 synergism is dependent upon
Smad2/3 activation (23, 38), we examined the ability of our
BMP15 variants to affect this response in COV434 cells.
Although wild type BMP15 promoted GDF9-dependent
Smad2/3 transcriptional activity in a dose-dependent manner,
the BMP15S:C variant could not potentiate a GDF9 effect (Fig.
2B). To ensure the BMP15S:C variant had bioactivity, we tested
its ability to stimulate the SMAD1/5/8 pathway in COV434
cells transfected with a BMP-responsive luciferase reporter. In
this system, the BMP15S:C protein was equally potent as wild
type BMP15 (Fig. 2C). As expected, GDF9 did not activate the
SMAD1/5/8 pathway. Together, these results indicate that
extracellular heterodimerization of mature GDF9 and BMP15
is possible, because simple co-addition of GDF9BMP15, but
not of GDF9BMP15S:C, resulted in potent synergism.
To further explore extracellular associations between GDF9
and BMP15, wemixed conditionedmedia from cells expressing
untagged pro-GDF9 with conditioned media from cells
expressing N-terminally poly-His-tagged pro-BMP15 and car-
ried out IMAC purification of the pro-BMP15. Under the mild
conditions used, the untagged GDF9 mature region was capa-
ble of associating and co-purifying with pro-BMP15, as evi-
denced by GDF9 immunoreactivity co-eluting off the IMAC
resin (Fig. 3A). No GDF9 immunoreactivity was detected when
BMP15 was purified alone (data not shown), and the untagged
GDF9 did not bind to the IMAC resin in the absence of the
poly-His-tagged BMP15 (Fig. 3B). It is clear from these results
that, like the mature proteins, the pro forms of GDF9 and
BMP15 are capable of associating extracellularly to form
pro-cumulin.
Intracellular Formation of Cumulin—GDF9 and BMP15 are
co-expressed in the oocyte throughout folliculogenesis and so
do not naturally exist in isolation (reviewed in Ref. 39). Thus,
heterodimerization of these two TGF- family members to
form cumulin is likely to occur during synthesis within the
oocyte, as well as after secretion into the extracellular space. In
the in vivo context, cumulin will be in a form where the mature
regions are noncovalently associated and will most likely act as
a pro/mature complex. To produce such a form (i.e. pro-cumu-
lin), we co-expressed N-terminally poly-His-tagged pro-
BMP15 with untagged pro-GDF9 and purified the noncovalent
pro-cumulin complex by IMAC. Theoretically, this approach
could lead to the purification of a mixture of pro-BMP15
homodimers and pro-cumulin. Quantification of the levels of
both the processedGDF9 andBMP15mature regions following
IMAC purification indicated a 3:1 ratio of pro-BMP15
homodimer:pro-cumulin heterodimer (data not shown).
Pro-cumulin Is a Potent Activator of Granulosa Cells via Both
SMAD Pathways—We next examined the potency of pro-cu-
mulin in ovarian GC bioassays. We compared pro-cumulin to
FIGURE 2. GDF9/BMP15 synergism is mediated by heterodimer forma-
tion. The BMP15 (S356C) covalent homodimer (BMP15S:C) does not synergize
withGDF9, in contrast towild typeBMP15,where clear synergism isobserved.
Bioactivity was assessed by [3H]thymidine incorporation in primary mouse
mural GC (A), Smad2/3-responsive luciferase reporter activity (B), or Smad1/
5/8 luciferase reporter activity, in COV434 humanGC (C). The various proteins
were produced in HEK-293T cells with N-terminal His tags attached to their
prodomains allowing purification by IMAC, followed by isolation of mature
domains by reverse-phase HPLC. BMP15, HPLC-purified human BMP15
mature region homodimer;GDF9, HPLC purified human GDF9mature region
homodimer; BMP15S:C, HPLC-purified human BMP15 (Ser-Cys) mature region
covalent homodimer.
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pro-GDF9, pro-BMP15, and pro-GDF9  pro-BMP15, after
quantitating each protein form relative to the level of the GDF9
mature region (data not shown). Pro-GDF9 alone was inactive
in promoting GC DNA synthesis, as shown previously (3), as
was pro-BMP15 alone (Fig. 4A). In contrast, pro-cumulin was
exceptionally potent on primary mouse mural GC, stimulating
a 3.8-fold increase in [3H]thymidine incorporation at the lowest
dose tested (1 ng/ml; Fig. 4A). Pro-cumulin was notably more
potent (6–12-fold) than pro-GDF9pro-BMP15 at all doses
examined.
To examine SMAD signaling by pro-cumulin, we conducted
transcriptional reporter assays using the human granulosa cell
line, COV434, as previously reported (3). Pro-cumulin dose-
dependently activated SMAD2/3 signaling in GC, producing
high levels of A3-Lux reporter activity at 50 and 100 ng/ml (Fig.
4B). Pro-GDF9 pro-BMP15 also dose-dependently activated
SMAD2/3 but did not reach the same levels of stimulation
as pro-cumulin. As expected, pro-GDF9 did not activate
SMAD2/3, because it is latent (3, 12). Interestingly, pro-cumu-
lin and pro-GDF9  pro-BMP15 promoted similar levels of
BRE-luciferase activation (reflecting the level of SMAD1/5/8
phosphorylation) as pro-BMP15 (Fig. 4C). As expected, GDF9
did not activate the SMAD1/5/8 pathway (Fig. 4C), and BMP15
did not activate the SMAD2/3 pathway (Fig. 4B).
Engineering Covalent Mature Cumulin—The pro-cumulin
preparation described above and that previously produced by
Peng et al. (24, 40) contain significant amounts of contaminat-
ing pro-BMP15 homodimer. This was due to the almost equal
propensity of monomeric BMP15 to homodimerize or het-
erodimerize (with GDF9) and the fact that the purification
strategies were directed against tagged BMP15 prodomains. To
overcome these limitations and to more conclusively examine
the biological function of cumulin, we undertook to engineer a
covalent form of cumulin, which could be fully purified from
contaminating BMP15 and GDF9. To produce such a protein,
we replaced Ser418 in GDF9 and Ser356 in BMP15 with the cor-
responding cysteine found in other TGF- proteins and co-ex-
pressed the resultant cDNAs in HEK293T cells. We have used
this approach before to produce human covalent mature
BMP15 (8). Both the pro-BMP15S:C and pro-GDF9S:C mutants
were produced with N-terminal poly-His tags; hence IMAC
FIGURE 3. GDF9 associates and co-purifies with BMP15 to form pro-
cumulin. Conditioned media containing untagged pro-GDF9 and N-termi-
nallyHis8-taggedpro-BMP15were combinedand subjected to IMACchroma-
tography. A, Western blot of resin load probed with Mab28 (specific for
humanBMP15), or the resin load, unboundedmaterial,wash, andelutedpeak
fraction, probed with Mab53 (specific for GDF9). B, Western blot for IMAC
chromatography of conditionedmedia containing only untagged pro-GDF9.
Shown are the resin load, unbound material, wash, and eluate, probed with
Mab53.
FIGURE 4. Bioactivity and SMAD signaling of pro-cumulin. A–C, dose-re-
sponse curves of the different pro-protein forms of GDF9, BMP15, and cumu-
lin. Bioactivity was assessed by [3H]thymidine incorporation in primary
mouse mural GC (A), Smad2/3-responsive luciferase reporter activity (B), or
Smad1/5/8 luciferase reporter activity (C) in COV434 human GC. The various
pro-proteins were produced in HEK-293T cells with N-terminal His tags
attached to their prodomains allowing purification by IMAC.
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purification of conditioned media from cells co-expressing
these proteins theoretically could result in the co-purification
of pro-GDF9 or pro-BMP15 homodimers, as well as the sought
after pro-cumulin. We decided to target the GDF9 and BMP15
mature regions for purification to avoid any potentially mis-
folded disulfide linked pro/mature complexes. This was
accomplished by a two-step procedure of IMAC chromatog-
raphy followed by reverse phase HPLC. This approach suc-
ceeded in resolving three distinct covalent species: mature
GDF9, mature cumulin, and mature BMP15 (Fig. 5A). This
can be concluded because Western analysis of the fractions
from the reverse phase HPLC purification indicated that
fractions 31–32 contained GDF9, but no BMP15; fractions
33–34 contained both GDF9 and BMP15 (i.e. cumulin),
whereas fractions 36–39 contained only BMP15 (Fig. 5B).
The silver-stained gels confirmed the presence of disulfide-
linked dimers, as the reduced bands at 15–18 kDa (Fig. 5C,
fractions 32–34 and 37) that migrated at 25–35 kDa without
reduction (Fig. 5D, fractions 32–34 and 37).
Covalent Mature Cumulin Is Potently Bioactive—Because
purified mature cumulin has not previously been produced, it
was important to determine its bioactivity, especially given its
form as a stabilized disulfide linked covalentmature region het-
erodimer. We initially tested the fractions across the reverse
phase HPLC profile for bioactivity in the mural GC assay. The
peak of bioactivity (Fig. 5E, fraction 34) coincidedwith the frac-
tion containing the peak of covalent cumulin protein (Fig. 5,
B–D, fraction 34).
We next directly compared the bioactivity of covalent
mature cumulin to the previously characterized noncovalent
pro-cumulin on GC. Mature cumulin was highly potent in the
range of different granulosa cell assays performed; in most
cases, it was more potent than pro-cumulin (Fig. 6). In the pri-
marymousemural granulosa cell assay of [3H]thymidine incor-
poration, covalent mature cumulin had an ED50 of 0.6 ng/ml,
whereas pro-cumulin had an ED50 of 4 ng/ml (Fig. 6A). Mature
covalent cumulin was also more effective than pro-cumulin at
promoting SMAD2 signaling in human COV434 cells, as
assessed by A3-Lux activity (Fig. 6B), whereas the two cumulin
forms were equipotent at promoting SMAD1/5/8 signaling
(Fig. 6C). Together, our analysis of noncovalent pro-cumulin
and covalent mature cumulin allows us to propose a model
whereby cumulin activates both SMAD pathways but
SMAD2/3 in particular (Fig. 7).
One of the physiological roles of oocyte-secreted GDF9 and
BMP15 is to direct granulosa cell differentiation toward the
cumulus cell phenotype (41), which can be characterized by
expression of genes required for cumulus cell mucification
(Ptx3,Has2, Tnfaip6, and Ptgs2) (42). Pro-cumulin and mature
covalent cumulin were notably more effective at promoting
mRNA expression of these genes in primary mouse mural GC
than pro-GDF9, pro-BMP15, or both combined (Fig. 6D).
Mature cumulin was more effective than pro-cumulin, partic-
ularly at promoting Ptx3mRNA expression (p	 0.05).
Pro-cumulin, but Not Mature Covalent Cumulin, Is a Potent
Stimulator of Oocyte Developmental Competence—To test our
human proteins in a model closer to the in vivo situation, we
isolated porcine cumulus-oocyte complexes from small
unstimulated ovarian follicles, treated them for 24 h with our
different proteins, and examined cumulus cell expansion and
oocyte developmental competence (capacity of the oocyte to
FIGURE 5. Engineering and bioactivity of covalent cumulin. Condi-
tioned media from cells co-expressing GDF9 and BMP15, both harboring
the appropriate Ser-Cys mutations, were subjected to IMAC chromatog-
raphy followed by reverse phase HPLC. A, absorbance profile at 280 nm
from the HPLC purification. B, Western blot of HPLC fractions probed for
GDF9 with Mab53 or for BMP15 with Mab28. C and D, silver-stained SDS-
PAGE gel of the HPLC fractions, run under reduced (C) or nonreduced (D)
conditions. E, bioactivity of the fractions (0.25 l of each 1-ml fraction)
across the HPLC profile, as measured by [3H]thymidine incorporation into
primary cultures of murine mural GC.
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support embryo development to day 7).With best practice IVM
and embryo production, this model of low oocyte developmen-
tal competence typically yields 10–20% blastocysts (13, 32).
Interestingly, when porcine cumulus-oocyte complexes are
used as the target, rather than cells in amonolayer (eithermural
granulosa or COV434 cells), the most bioactive protein was
noncovalent pro-cumulin and not covalent mature cumulin
(Fig. 8). For cumulus expansion, the only protein that caused a
significant increase was pro-cumulin (Fig. 8A). Exposure of
oocytes to 20 ng/ml pro-cumulin for 24 h improved oocyte
quality as assessed by a substantial improvement in capacity to
support embryo development to the blastocyst (2.3-fold; 28-
63%; p	 0.05; Fig. 8B) and hatched blastocyst stages (3.8-fold;
5–19%; p	 0.05; Fig. 8C). Therewas no significant difference in
blastocyst rateswhen oocyteswere treatedwith 20 or 100 ng/ml
pro-cumulin (63 and 55%, respectively) or mature cumulin (32
and 39%, respectively). No other treatment improved oocyte
developmental competence, although pro-GDF9  pro-
BMP15 tended to increase blastocyst and hatched blastocyst
rates (p
 0.05; Fig. 8C). There was no effect of any treatments
FIGURE 6. Themature domain of covalent cumulin ismore potent than pro-cumulin onGC. The pro-cumulin preparationwas produced in HEK-293T cells
with aN-terminal His tag in theprodomain allowingpurificationby IMAC. Togenerate purifiedmature cumulin, the IMACproductwas subsequently subjected
to reverse phase HPLC, generating a highly pure mature domain protein with fixed heterodimer architecture (mature covalent cumulin). Bioactivity was
assessedby [3H]thymidine incorporation inprimarymousemuralGC (A), Smad2/3-responsive luciferase reporter activity (B), andSmad1/5/8 luciferase reporter
activity in COV434 humanGC (C), andmouse primarymural GCmRNA expression of genes associatedwith cumulus cell differentiation (D), Ptx3, Tnfaip6,Has2,
and Ptgs2 (all proteins at 100 ng/ml, except pro-GDF9 pro-BMP15, which were added at 50 ng/ml each). The bars with different letters indicate significant
differences at p	 0.05 within the same graph.
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on subsequent blastocyst quality as assessed by blastocyst cell
numbers (Fig. 8D).
Molecular Modeling and Analysis of Cumulin Assembly—To
provide molecular insights into cumulin assembly, stability,
and potential receptor-binding properties, we performed ho-
mology modeling to obtain structural models of homo- and
heterodimeric forms of GDF9 and BMP15. Structure templates
were selected on the basis of sequence homology to BMPs and
GDFs with known structure in the Protein Data Bank. The
models of mature GDF9 (Fig. 9,A and B) and BMP15 (Fig. 10,A
and B) exhibit the canonical butterfly-shaped architecture of
TGF- ligands. The structure of the monomeric subunits is
FIGURE 7. Hypothesized model of human cumulin formation and signal-
ing. BMP15 and GDF9 are co-expressed in the oocyte throughout most of
oogenesis. a, during synthesis, the prodomains of BMP15 and GDF9 direct
folding and dimerization of their respective mature domains. b, dimeric pre-
cursors are cleaved by furin-like proteases, and then BMP15 and GDF9 are
secreted from the oocyte noncovalently associated with their prodomains,
forming their respective pro-forms. The pro-cumulin heterodimer is likely to
assemblewithin the oocyte but can also form in the extracellular space (ECM).
In isolation, human pro-GDF9 is latent, and activation is dependent upon
heterodimerization with BMP15 to form cumulin. Following prodomain dis-
placement (c), cumulin activates both SMAD2/3 and SMAD1/5 transcription
factors (e), presumably through a receptor complex involving two BMPRII
receptors, an ALK6 receptor and an ALK5/4 receptor, on cumulus GC and
mural GC (d). Pro-cumulin andmature cumulin exhibit differing potencies on
different granulosa cell lineages.
FIGURE 8. Pro-cumulin, but notmature cumulin, is a potent stimulator of
oocyte developmental competence.Aporcine in vitro experimentalmodel
of low oocyte developmental competence was used to examine the effect of
the various growth factors on oocyte quality. Porcine cumulus-oocyte com-
plexes were treated with vehicle, 20 ng/ml pro-cumulin, 20 ng/ml mature
covalent cumulin, 100 ng/ml pro-GDF9, 100 ng/ml pro-BMP15, or 100 ng/ml
of each of pro-GDF9 pro-BMP15 for the first 22 h of oocyte in vitromatura-
tion. A, morphological cumulus expansion was assessed and scored at 22 h
according to the Vanderhyden criteria. Effects of the treatments on oocyte
development competence were examined by assessing embryo develop-
ment on day 7. B and C, blastocyst rate (B) and hatching blastocyst rate (C)
[hatching or hatched blastocysts], both expressed as a percentage of the
number of cleaved embryos.D, average blastocyst cell number. All values are
represented as means  S.E. from five replicate experiments. The bars with
different letters indicate significant differences at p 	 0.05 within the same
graph.
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defined by the cysteine knot, which results in three loops ema-
nating from this central motif. The two loops running in paral-
lel form -sheets, whereas the third loop, which emanates from
the cysteine core in the opposite direction, folds into an-helix.
Themonomer architecture is also often comparedwith an open
hand, with the -sheets forming fingers 1 and 2 and the -helix
forming the wrist (Figs. 9,A and B, and 10,A and B). The dimer
assembly can then be envisioned as the inner sides of the two
hands coming together at palm and wrist.
Unlike most TGF- ligands, GDF9 and BMP15 lack the
cysteine residue that forms an intermolecular disulfide
bond, locking the dimer assembly (this cysteine is replaced
by an isosteric serine in both GDF9 and BMP15). This
unique feature, together with the very high sequence conser-
vation across the GDF9 and BMP15 dimer interfaces (Figs.
9C and 10C), enables these growth factors to heterodimerize
to form cumulin (Fig. 11, A and B). Importantly, the cumulin
model shows a dimerization interface (Fig. 11C) identical to
homodimeric GDF9 and BMP15 (Figs. 9C and 10C, respec-
tively), indicating that formation of the heterodimer is pos-
sible and that the stability of such a complex is likely indis-
tinguishable from the homodimeric forms. Production of
covalent cumulin also appears likely based upon our model-
ing, because in silico exchange of the two serine residues
(Ser418 in GDF9 and Ser356 in BMP15; Fig. 11B) locates both
sulfur atoms sufficiently close to form a thioether bond with-
out requiring conformational or large structural rearrange-
ments of the dimer architecture (Fig. 11D).
Finally, analysis of our homology models indicates that the
binding sites for type I receptors within the “wrist” regions are
distinct in cumulin, relative to its homodimeric ancestors (Figs.
11B, 9B, and 10B). This is due to the fact that, in contrast to the
type II receptor epitopes, the wrist or type I receptor-binding
FIGURE 9. Homology model of mature GDF9. A, ribbon plot of human
matureGDF9highlightingthecanonicaldimerarchitecture.Thetwomono-
mer subunits of the homodimer are colored in red and orange. The poten-
tial binding epitopes for the type I (wrist) and type II (knuckle) receptors
are marked. The six cysteine residues forming the characteristic cysteine
knot motif, as well as the serine residues replacing the cysteine residues,
which are involved in the intermolecular disulfide bond found in other
TGF-members, are shown as sticks. B, as in A but rotated around the x axis
by 90°. C, detail of the GDF9 dimer interface showing that interfacial amino
acid residues are highly conserved between GDF9 and BMP15 (see also
Fig. 10), suggesting that heterodimer formation (see Fig. 11) is very likely
not impaired by steric or chemical restraints resulting from differences in
the dimer interface.
FIGURE 10.Homologymodel of mature BMP15. A, ribbon plot of human
mature BMP15 showing the canonical dimer architecture. The two mono-
mer subunits of the homodimer are colored in light and dark green. The
potential binding epitopes for the type I (wrist) and type II (knuckle) recep-
tors are indicated. The six cysteine residues (colored in yellow) forming the
characteristic cysteine knot motif, as well as the serine residues replacing
the cysteine residues, which are involved in the intermolecular disulfide
bond found in other TGF- members, are shown as sticks. B, as in A but
rotated around the x axis by 90°. C, detailed view of the BMP15 dimer
interface showing that interfacial amino acid residues are highly con-
served with those found in GDF9 (see also Fig. 9), suggesting that cumulin
formation (see Fig. 11) is very likely not impaired by steric or chemical
restraints by differences in the dimer interface.
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site is built from both monomer subunits. In cumulin, this
epitope therefore presents a chimera with unique amino acid
composition not found in either homodimeric growth factor
ancestor. These differences may alter type I receptor affinity
and/or specificity for cumulin and contribute to its enhanced
signaling capacity, particularly in comparison to latent human
GDF9.
Discussion
In females, GDF9 and BMP15 are essentially only expressed
in oocytes where they are co-expressed throughout most of
oogenesis and so do not naturally exist in isolation. Moreover,
given their high sequence homology, these key growth factors
can be expected to interact with each other and hence should
generally be considered as acting together. There is ample evi-
dence for interactions between GDF9 and BMP15 at genetic (1,
16, 18), biochemical (19, 20), and functional levels (20–23). A
putative BMP15-GDF9 heterodimer was first modeled by
McNatty et al. (1) in 2004. Most recently, Peng et al. (24) pro-
ducedGDF9-BMP15 heterodimers with potent bioactivity.We
have pointed out a number of potential methodological and
interpretation deficiencies in that study (43), including that the
preparation contained other protein forms, and the only evi-
dence presented for formation of a heterodimer was co-immu-
noprecipitation of the two proteins. In the current study, we
have conducted detailed molecular modeling of heterodimer
assembly and succeeded in producing two heterodimeric
forms: pro-cumulin and mature covalent cumulin. Both forms
are particularly potent on GCs acting via both the SMAD2/3
and SMAD1/5/8 pathways and show differential actions on
mural GC versus cumulus GC.
The co-addition of separately expressed GDF9 and BMP15
homodimers elicits a potent synergistic response on GC
(20–23). The results of the current study provide strong evi-
dence that the basis for such synergism is formation of the
cumulin heterodimer. Such GDF9/BMP15 synergism has
been described by others as the action of two homodimers
(24). Our results do not support this contention. We deduce
this from the observation that the BMP15S:C covalent
homodimer, which cannot heterodimerize with GDF9, does
not synergize with wild type GDF9, in contrast to wild type
BMP15. The BMP15S:C mutant in all other aspects resembles
wild type BMP15. Furthermore, both pro-cumulin and
mature covalent cumulin elicited a more potent response
than the synergistic effects of co-addition of wild type GDF9
and BMP15 homodimers. Using the novel covalent cumulin
alleviates any concerns arising from studying solely a nonco-
valent heterodimer, which may exist in an equilibrium
between homodimers and heterodimers, as we previously
discussed (43). This leads us to hypothesize that the process
of heterodimerization is the mechanism of activation of the
otherwise latent GDF9 in the human.
Although inhibin A and B are the other major naturally
occurring TGF- heterodimers (5), it is possible to co-express
other TGF- ligands and force their dimerization and in so
doing generate more biologically potent proteins. Within the
BMP subgroup, BMP2/7 (44, 45), BMP2/6 (46), and BMP7/
GDF7 (47) heterodimers are all reported as more potent or as
exhibiting altered bioactivity, in comparison with a combina-
tion of homodimers. There are a number of possible mecha-
nisms to account for greater potency of heterodimers. First, a
heterodimermay have a decreased binding affinity for extracel-
lular BMP binding proteins, which commonly act as antago-
nists. Many of these antagonists act themselves as obligate or
nonobligate dimers and thus require a symmetrical homodimer
for maximal binding affinity. Another explanation is that
TGF- ligands tend to have a high affinity for either a type I or
for a type II receptor, often leading to a strict sequential binding
mechanism. A heterodimer, however, could combine a high
affinity binding site for a type I and a type II receptor within the
one dimeric ligand, thereby greatly enhancing the overall affin-
FIGURE 11.Molecular modeling of mature cumulin. A, ribbon plot of the homology model of humanmature cumulin showing the butterfly-shaped dimer
architecture and with the monomer subunits colored in red and green. Structural features and the potential binding epitopes for the type I (wrist) and type II
(knuckle) receptors are indicated. The six cysteine residues forming the characteristic cysteine knotmotif are shown as sticks. B, as in A but rotated around the
x axis by 90°. C, detail of the cumulin dimer interface showing that, despite lacking the intermolecular disulfide bond present in most other TGF- ligands,
similar polar andhydrophobic interactions stabilize dimer assembly.D, production of covalent cumulin appears possible, because in silico exchangeof the two
serine residues (Ser418 in GDF9 and Ser356 in BMP15) with cysteines locates both sulfur atoms sufficiently close to form a thioether bond without requiring
conformational or large structural rearrangements of the dimer architecture.
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ity to its cell surface receptors. Finally, because of its inherent
asymmetry, a heterodimeric ligand ismore prone to recruit two
different type I receptors into the signaling complex. For exam-
ple, the cumulin receptor complex (Fig. 7) is predicted to com-
prise two BMPRII receptors: one ALK4/5/7 receptor, which is
necessary for the activation of the SMAD2/3 pathway, and one
ALK6 receptor, which is needed for SMAD1/5/8 signaling, as
originally hypothesized by McNatty et al. (1).
An open question prior to this study was whether cumulin
could only form inside the oocyte orwhether itmight also spon-
taneously assemble fromhomodimericGDF9 andBMP15pres-
ent in the extracellular space. The latter seemed feasible
because GDF9 and BMP15 naturally form transient dimers,
whose dimer architecture is not fixed by an intermolecular
disulfide bond. Indeed, we observed that the two wild type
homodimeric proteins, separately produced and purified, syn-
ergize via a process of heterodimer formation. High resolution
structure studies of different BMPs provide a possible explana-
tion for GDF9 and BMP15 disassembly and subsequent cumu-
lin formation. Specifically, the structures show that the inter-
face between the monomeric halves of TGF- proteins
is considerably hydrated, which is unusual compared with
the water-free hydrophobic core of soluble proteins (48–51).
The localization of these conserved water molecules in the
dimerization interface around the central cysteine knot
likely limits the stability of the dimer; however, in the case of
covalent BMPs, a full disassembly of the dimer is prevented
because of the covalent linkage via the intermolecular disul-
fide. However, because GDF9 and BMP15 lack this bond,
both factors potentially undergo full disassembly and reas-
sembly, which, when both factors are simultaneously present
(usual situation in most mammals), would yield an equilib-
rium-based mixture of homo- and heterodimers unless
steric restraints specifically interfere with heterodimer for-
mation. The latter seems highly unlikely, however, given the
fact that the interface residues are highly conserved between
GDF9 and BMP15. Together, this evidence suggests that the
formation of cumulin in vivo might, at least in part, occur
postsecretion from the oocyte in the extracellular matrix of
the granulosa and cumulus cells. If so, it seems plausible that
the nature and composition of the extracellular matrix,
which in turn is affected by in vivo and in vitro context, is
likely to affect cumulin assembly and bioactivity.
Two remarkable features of cumulin bioactivity is its capac-
ity to activate both the SMAD2/3 and SMAD1/5/8 signaling
pathways, as well as its enhanced signaling potency, in particu-
lar when compared with the GDF9 and BMP15 homodimers.
On isolated mural GCs, mature covalent cumulin was even
more potent than pro-cumulin, particularly in terms ofGCpro-
liferation, which is consistent with its enhanced SMAD2/3 sig-
naling (29). Dual SMAD pathway activation by cumulin is in
disagreement with Peng et al. (24), who claimed that theGDF9-
BMP15 heterodimer binds to, but does not activate, the ALK6
receptor. The form of heterodimer that Peng et al. (24) pro-
duced has an epitope tag (either FLAG or myc) incorporated
into the N terminus of the mature region. Although this
appears to not impede BMP15 homodimer bioactivity (52), the
effects of the GDF9 (myc) and BMP15 (FLAG) tags on het-
erodimer activity are unknown. In contrast, covalent mature
cumulin does not contain any tags, and pro-cumulin incorpo-
rates a tag only at the N terminus of the BMP15 prodomain.
Hence, in all forms of GDF9, BMP15, or cumulin used in the
current study, the amino acid sequence of the mature region is
identical to the wild type sequence (apart from the Ser-Cys
mutation to form covalent dimers). The lack of any modifica-
tions to our GDF9 and BMP15mature regionsmay also explain
why we are able to detect synergism between separately
expressed and purified pro-GDF9 and pro-BMP15 (current
study), whereas others do not (24, 53).
An intriguing and important observation from the current
study is that when cumulus-oocyte complexes were treated,
only the pro-cumulin form improved oocyte quality, as assessed
by subsequent embryo yield, whereas mature covalent cumulin
did not, despite being exceptionally potent on mural GC.
Clearly, pro-cumulin contains the prodomains of GDF9 and
BMP15 as part of a complex, whereas mature cumulin is an
isolated mature region heterodimer (Fig. 3). These results are
entirely consistent with our recent observation that pro-
BMP15, but not mature domain BMP15 nor mature domain
mouse GDF9, enhances oocyte developmental competence
(54, 55). It is well established that prodomains of TGF-
superfamily growth factors have important roles in protein
folding and regulation of bioactivity (56, 57). In particular,
interactions of the prodomains of cumulin with the special-
ized extracellular matrix of cumulus GC may facilitate pres-
entation of the heterodimeric mature domain to its recep-
tors. In support of these concepts, we have shown that
pro-GDF9 binds strongly to heparin, suggesting that certain
heparan sulfate proteoglycans may act as co-receptors for pro-
GDF9, pro-BMP15, and pro-cumulin (58). Hence, the differen-
tial activities of pro-cumulin andmature cumulin onmural GC
versus cumulus GCmay be attributed to differential expression
of heparan sulfate proteoglycans and/or type I or II receptors in
these GC.
Finally, the current study also has significant practical impli-
cations for reproductive medicine and advanced breeding in
domestic animals. The development of purified and highly
potent pro-cumulin is likely to prove an important additive for
oocyte IVM (59). IVM is an assisted reproductive technology
that generates viable embryos using reduced or no exogenous
ovarian hormone stimulation of the patient. IVM is thus an
important adjunct technology to in vitro fertilization. To make
IVMmore clinically viable, including in fertility preservation in
cancer survivors, an additive such as pro-cumulin is needed to
improve the efficiency of IVM (60). We and others have shown
that addition of “native” oocyte-secreted factors (e.g. pro-
BMP15 or pro-GDF9) to IVM enhances oocyte quality, having
profound effects on embryo development and fetal survival (13,
54, 55, 61–64). This study is the first report on the effects of
cumulin on oocyte quality. We carefully chose to use an estab-
lished porcinemodel of low oocyte developmental competence
using oocytes from growing antral follicles to better recapitu-
late the human scenario. The addition of pro-cumulin led to a
major improvement in oocyte quality, more than doubling
embryo yield, which, if translatable to human oocytes, would
have a large impact on clinical IVM and oncofertility.
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